The
unit of Aurobindo Pharmaceuticals in Srikakulam district of Andhra Pradesh,
which is an active pharmaceutical ingredient (API) facility has received warning letter from USFDA.
The unit is
engaged in manufacturing and selling of the active drugs and their
intermediates.
The warning letter issued by USFDA based on the inspection of
the facility which was conducted in Feb 2019.
The details of the observations of the warning letters are not disclosed
by the authority/company.
The company said that they are working on resolving the GMP
issues on top priority and all of the observations shall be closed shortly.
The company informed that they are committed to maintain highest
standard of the quality system during manufacturing of the pharmaceutical goods
across the globe.
The company Aurobindo Pharma was founded by Mr. K. Nityananda
Reddy in the year of 1986. It’s head office is located Hyderabad city in
Telangana State.
The major segments of the portfolio of Aurobindo ltd are
anti-allergic, gastroenterology etc.
The Aurobindo Ltd is a leader in the
manufacturer and sell of the semi-synthetic Penicillins.
No comments:
Post a Comment